Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB6432
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TQB6432 is a biosimilar monoclonal antibody developed by Chia Tai Tianqing (Sino Biopharm) that targets CD20 (B-lymphocyte antigen CD20). It is designed as a biosimilar of obinutuzumab (Gazyva). TQB6432 is a glycoengineered, Type II anti-CD20 humanized IgG1 monoclonal antibody. Upon binding to CD20 on the surface of pre-B and mature B-lymphocytes, it mediates B-cell depletion through direct cell death (apoptosis) and immune-mediated effector mechanisms, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). TQB6432 is being developed for the treatment of B-cell malignancies, specifically follicular lymphoma, and is currently in preclinical development.
- Other names
- Obinutuzumab biosimilar
02
Targets
Beyond the preview
Go deeper on TQB6432.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB6432.